Trulicity FDA Safety Label Change Victoza (liraglutide) subcutaneous daily injection FDA Approval Year: 2010 Victoza FDA Safety Label Change Xultophy 100/3.6 (insulin degludec and liraglutide) subcutaneous daily injection FDA Approval Year: 2016 Xultophy FDA Safety Label Change GLP-1 Meds for Weight Loss with New Pulmonary Aspiration Warnings Saxenda (liraglutide) subcutaneous daily injection FDA Approval Year: 2014 Saxenda FDA Safety Label Change Wegovy (semaglutide) subcutaneous weekly injection FDA Approval Year: 2021 Wegovy FDA Safety Label Change Zepbound (tirzepatide) subcutaneous weekly injection FDA Approval Year: 2022 Zepbound FDA Safety Label Change For more on this topic, check out: Should You Stop Taking Ozempic Before Surgery? Have you taken any of the GLP-1 meds listed on this page
Among those not currently using GLP-1 medications, 4% of respondents said they have concrete plans to begin using GLP-1 in the next 12 months, while an additional 13% said they are considering starting the medication
Concurrently, imaging data suggest that liraglutide treatment leads to reductions in ovarian volume and antral follicle count (AFC), indicating that ovarian morphology can undergo measurable changes as the metabolic-endocrine environment improves (96, 124, 130)
Slowed Stomach Emptying: GLP-1 slows the rate at which your stomach empties, keeping you fuller for longer and leading to a gradual rise in blood sugar after eating
Always follow your specific product's Patient Information Leaflet
